Biotech Values

[dewophile]

zgen
the company mentioned there would be cost cuts on the Q1 cc. however, i am a bit surprised by the depth of the cuts. here's a bit more color (note that dropping oncology does not mean a no-go for IL-21, and in fact there is a poster at the melanoma conference later this month):

http://www.xconomy.com/seattle/2009/04/29/zymogenetics-cuts-one-third-of-workforce-to-hold-onto-cash/